21 CFR 10.20 - Submission of documents to Division of Dockets Management; computation of time; availability for public disclosure.
(a) A submission to the Division of Dockets Management of a petition, comment, objection, notice, compilation of information, or any other document is to be filed in four copies except as otherwise specifically provided in a relevant Federal Register notice or in another section of this chapter. The Division of Dockets Management is the agency custodian of these documents.
(b) A submission is to be signed by the person making it, or by an attorney or other authorized representative of that person. Submissions by trade associations are also subject to the requirements of § 10.105(b).
(c) Information referred to or relied upon in a submission is to be included in full and may not be incorporated by reference, unless previously submitted in the same proceeding.
(1) A copy of an article or other reference or source cited must be included, except where the reference or source is:
(i) A reported Federal court case;
(ii) A Federal law or regulation;
(iii) An FDA document that is routinely publicly available; or
(iv) A recognized medical or scientific textbook that is readily available to the agency.
(2) If a part of the material submitted is in a foreign language, it must be accompanied by an English translation verified to be complete and accurate, together with the name, address, and a brief statement of the qualifications of the person making the translation. A translation of literature or other material in a foreign language is to be accompanied by copies of the original publication.
(3) Where relevant information is contained in a document also containing irrelevant information, the irrelevant information is to be deleted and only the relevant information is to be submitted.
(4) Under § 20.63 (a) and (b), the names and other information that would identify patients or research subjects are to be deleted from any record before it is submitted to the Division of Dockets Management in order to preclude a clearly unwarranted invasion of personal privacy.
(5) Defamatory, scurrilous, or intemperate matter is to be deleted from a record before it is submitted to the Division of Dockets Management.
(6) The failure to comply with the requirements of this part or with § 12.80 or § 13.20 will result in rejection of the submission for filing or, if it is filed, in exclusion from consideration of any portion that fails to comply. If a submission fails to meet any requirement of this section and the deficiency becomes known to the Division of Dockets Management, the Division of Dockets Management shall not file the submission but return it with a copy of the applicable regulations indicating those provisions not complied with. A deficient submission may be corrected or supplemented and subsequently filed. The office of the Division of Dockets Management does not make decisions regarding the confidentiality of submitted documents.
(d) The filing of a submission means only that the Division of Dockets Management has identified no technical deficiencies in the submission. The filing of a petition does not mean or imply that it meets all applicable requirements or that it contains reasonable grounds for the action requested or that the action requested is in accordance with law.
(e) Except as provided in § 10.31(b), all submissions to the Division of Dockets Management will be considered as submitted on the date they are postmarked or, if delivered in person during regular business hours, on the date on which they are delivered, unless a provision in this part, an applicable Federal Register notice, or an order issued by an administrative law judge specifically states that the documents must be received by a specified date, e.g., § 10.33(g) relating to a petition for reconsideration, in which case they will be submitted on the date received.
(g) FDA ordinarily will not acknowledge or give receipt for documents, except:
(1) Documents delivered in person or by certified or registered mail with a return receipt requested; and
(h) Saturdays, Sundays, and Federal legal holidays are included in computing the time allowed for the submission of documents, except that when the time for submission expires on a Saturday, Sunday, or Federal legal holiday, the period will be extended to include the next business day.
(i) All submissions to the Division of Dockets Management are representations that, to the best of the knowledge, information, and belief of the person making the submission, the statements made in the submission are true and accurate. All submissions are subject to the False Reports to the Government Act ( 18 U.S.C. 1001) under which a willfully false statement is a criminal offense.
(j) The availability for public examination and copying of submissions to the Division of Dockets Management is governed by the following rules:
(1) Except to the extent provided in paragraphs (j)(2) and (3) of this section, the following submissions, including all supporting material, will be on public display and will be available for public examination between 9 a.m. and 4 p.m., Monday through Friday. Requests for copies of submissions will be filed and handled in accordance with subpart C of part 20:
(ii) Comments on petitions, on documents published in the Federal Register, and on similar public documents.
(iii) Objections and requests for hearings filed under part 12.
(iv) Material submitted at a hearing under § 12.32(a)(2) and parts 12, 13, and 15.
(i) Material prohibited from public disclosure under § 20.63 (clearly unwarranted invasion of personal privacy) and, except as provided in paragraph (j)(3) of this section, material submitted with objections and requests for hearing filed under part 12, or at a hearing under part 12 or part 13, or an alternative form of public hearing before a public advisory committee or a hearing under § 12.32(a) (2) or (3), of the following types will not be on public display, will not be available for public examination, and will not be available for copying or any other form of verbatim transcription unless it is otherwise available for public disclosure under part 20:
(a) Safety and effectiveness information, which includes all studies and tests of an ingredient or product on animals and humans and all studies and tests on the ingredient or product for identity, stability, purity, potency, bioavailability, performance, and usefulness.
(b) A protocol for a test or study.
(c) Manufacturing methods or processes, including quality control procedures.
(d) Production, sales distribution, and similar information, except any compilation of information aggregated and prepared in a way that does not reveal confidential information.
(e) Quantitative or semiquantitative formulas.
(f) Information on product design or construction.
(ii) Material submitted under paragraph (j)(2) of this section is to be segregated from all other submitted material and clearly so marked. A person who does not agree that a submission is properly subject to paragraph (j)(2) may request a ruling from the Associate Commissioner for Public Affairs whose decision is final, subject to judicial review under § 20.48.
(3) Material listed in paragraph (j)(2)(i) (a) and (b) of this section may be disclosed under a protective order issued by the administrative law judge or other presiding officer at a hearing referenced in paragraph (j)(2)(i). The administrative law judge or presiding officer shall permit disclosure of the data only in camera and only to the extent necessary for the proper conduct of the hearing. The administrative law judge or presiding officer shall direct to whom the information is to be made available (e.g., to parties or participants, or only to counsel for parties or participants), and persons not specifically permitted access to the data will be excluded from the in camera part of the proceeding. The administrative law judge or other presiding officer may impose other conditions or safeguards. The limited availability of material under this paragraph does not constitute prior disclosure to the public as defined in § 20.81, and no information subject to a particular order is to be submitted to or received or considered by FDA in support of a petition or other request from any other person.
Title 21 published on 2015-12-03
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR Part 10 after this date.
- 21 CFR 330.14 — Additional Criteria and Procedures for Classifying OTC Drugs as Generally Recognized as Safe and Effective and Not Misbranded.
- 21 CFR 13.45 — Examination of Administrative Record.
- 21 CFR 100.1 — Petitions Requesting Exemption From Preemption for State or Local Requirements.
- 21 CFR 15.45 — Examination of Administrative Record.
- 21 CFR 12.94 — Receipt of Evidence.
- 21 CFR 15.25 — Written Submissions.
- 21 CFR 60.34 — FDA Action on Petitions.
- 21 CFR 12.120 — Initial Decision.
- 21 CFR 13.20 — Submissions to a Board.
- 21 CFR 12.105 — Examination of Record.
- 21 CFR 14.35 — Written Submissions to an Advisory Committee.
- 21 CFR 60.30 — Filing, Format, and Content of Petitions.
- 21 CFR 10.35 — Administrative Stay of Action.
- 21 CFR 12.24 — Ruling on Objections and Requests for Hearing.
- 21 CFR 170.39 — Threshold of Regulation for Substances Used in Food-Contact Articles.
- 21 CFR 314.153 — Suspension of Approval of an Abbreviated New Drug Application.
- 21 CFR 10.115 — Good Guidance Practices.
- 21 CFR 10.33 — Administrative Reconsideration of Action.
- 21 CFR 13.30 — Proceedings of a Board.
- 21 CFR 10.85 — Advisory Opinions.
- 21 CFR 314.93 — Petition to Request a Change From a Listed Drug.
- 21 CFR 12.45 — Notice of Participation.
- 21 CFR 12.96 — Briefs and Arguments.
- 21 CFR 12.32 — Request for Alternative Form of Hearing.
- 21 CFR 101.69 — Petitions for Nutrient Content Claims.
- 21 CFR 10.30 — Citizen Petition.
- 21 CFR 12.80 — Filing and Service of Submissions.
- 21 CFR 314.151 — Withdrawal of Approval of an Abbreviated New Drug Application Under Section 505(j)(5) of the Act.
- 21 CFR 10.31 — Citizen Petitions and Petitions for Stay of Action Related to Abbreviated New Drug Applications, Certain New Drug Applications, or Certain Biologics License Applications.
Title 21 published on 2015-12-03.
The following are only the Rules published in the Federal Register after the published date of Title 21.
For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.